EverCommerce stock slides 6% in regular trade after CEO share-sale disclosure hits tape
2 January 2026
1 min read

EverCommerce stock slides 6% in regular trade after CEO share-sale disclosure hits tape

NEW YORK, January 2, 2026, 14:49 ET — Regular session

EverCommerce Inc shares were down 6.6% at $11.31 in afternoon trading on Friday, after hitting an intraday low of $10.89. The Nasdaq 100 tracker was little changed, while the S&P 500 ETF was up about 0.2%.

The move matters because EverCommerce is a smaller, thinly traded software name, where swings can be sharper than the broader market on modest news flow. A steep drop early in the year can also draw attention from investors resetting positions after year-end.

Traders have been parsing a fresh insider-trading disclosure from the company’s founder and chief executive, which can influence sentiment even when the transactions are relatively small.

A Form 4 filing showed CEO Eric Remer sold 6,571 shares on Dec. 29, 7,303 shares on Dec. 30 and 5,326 shares on Dec. 31 at weighted average prices around $12.07 to $12.20, for a total of 19,200 shares. “All sale transactions reported herein were made pursuant to a Rule 10b5-1 trading plan dated June 12, 2025,” the filing said, and it listed Remer as holding about 2.78 million shares directly after the sales. 1

A Rule 10b5-1 plan is a pre-arranged trading program that can let insiders buy or sell shares automatically, helping separate transactions from day-to-day headlines. Investors often still track the pace and pattern of insider selling for clues on executive confidence and stock supply.

Based on the reported prices in the filing, the three-day sale was worth about $233,000, a small amount relative to EverCommerce’s roughly $2 billion market value. The stock’s outsized drop on Friday suggested broader risk appetite and liquidity were also in play.

EverCommerce sells vertically tailored software to service-based businesses and said it supports more than 740,000 customers across home, health and wellness verticals. In its most recent quarterly update, the company forecast fourth-quarter revenue of $148 million to $152 million and adjusted EBITDA — a profit measure that strips out interest, taxes and depreciation and some items management excludes — of $39.5 million to $41.5 million, and said its board increased its repurchase authorization by $50 million to $300 million through Dec. 31, 2026. 2

The shares have traded in a 52-week range of $7.66 to $14.41, according to Yahoo Finance, keeping Friday’s selloff within the bounds of a volatile year for the stock. 3

Looking ahead, EverCommerce’s next earnings date has not been announced, and market calendars currently estimate a mid-March window. 4

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
PepsiCo stock dips today as PEP lags staples, with earnings and dividend in focus
Previous Story

PepsiCo stock dips today as PEP lags staples, with earnings and dividend in focus

Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade
Next Story

Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade

Go toTop